Gilead Steps In To Buy CV Therapeutics | March 16, 2009 Issue - Vol. 87 Issue 11 | Chemical & Engineering News
Volume 87 Issue 11 | p. 22 | Concentrates
Issue Date: March 16, 2009

Gilead Steps In To Buy CV Therapeutics

Department: Business

Gilead Sciences has agreed to acquire CV Therapeutics for $20 per share in cash, an offer that trumps the unsolicited bid of $16 per share made late last year by Japanese drugmaker Astellas Pharma. CV's board unanimously approved the Gilead deal, which is valued at approximately $1.4 billion. CV develops small-molecule drugs for cardiovascular disease. Its approved products include Ranexa, a treatment for chronic angina. Gilead, which mostly markets HIV treatments, says CV strengthens its growing cardiovascular portfolio.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment